{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:26Z","timestamp":1793317586122,"version":"4.5.0"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inflammation is a key driver of coronary syndromes across the continuum from chronic coronary syndromes to acute coronary syndromes. It contributes to atherogenesis, plaque destabilization, and ischaemic events and influences myocardial injury, repair, and remodelling. Inflammatory activity is further amplified by metabolic and autoimmune comorbidities such as diabetes, obesity, and connective tissue diseases, with obesity representing a major driver of chronic low-grade inflammation through adipose tissue dysfunction and cytokine activation, while psychosocial stress and environmental exposures including air pollution serve as additional triggers. Genetic variations, including human leucocyte antigen genotypes, modulate individual susceptibility to vascular inflammation and myocardial injury. This expert consensus from the European Society of Cardiology\u2019s Association for Acute CardioVascular Care summarizes the current understanding of inflammation across the full spectrum of coronary syndromes, including underlying mechanisms, relevant biomarkers, and imaging approaches that characterize vascular inflammation, and integrates insights from experimental and clinical studies. Importantly, this document provides explicit consensus-based guidance on when, how, and in whom inflammation should be assessed and treated in routine clinical practice. While the causal association between inflammation and atherosclerotic cardiovascular disease is well established, pharmacological modification of inflammation has produced conflicting evidence. Some agents, such as low-dose colchicine, have demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent. Other anti-inflammatory therapies have not shown clinical benefit, whereas selective cytokine inhibition with canakinumab has reduced cardiovascular risk at the cost of increased infection rates. The present manuscript also focuses on the evaluation of inflammatory activity in cardiovascular patients in routine clinical practice. It further discusses criteria for patient selection and clinical decision-making regarding the introduction of anti-inflammatory therapy in individuals with established atherosclerotic cardiovascular disease.<\/jats:p>","DOI":"10.1093\/ehjacc\/zuag086","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:41:03Z","timestamp":1784979663000},"page":"788-803","source":"Crossref","is-referenced-by-count":0,"title":["Inflammation in coronary syndromes in clinical practice: a clinical consensus statement of the Association for Acute Cardiovascular Care of the European Society of Cardiology, the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, the European Society of Cardiology Council on Basic Cardiovascular Science, and the European Society of Cardiology Council for Cardiology Practice"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5288-9687","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Roubille","sequence":"first","affiliation":[{"name":"PhyMedExp, Cardiology Department, University of Montpellier, INSERM U1046, CNRS UMR, 9214, INI-CRT , 371 avenue du doyen Gaston Giraud, 34295 cedex 05 Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Alexander","family":"Kharlamov","sequence":"additional","affiliation":[{"name":"De Haar Research Task Force , Van der Neerstraat 34B, 2525CS The Hague ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-994X","authenticated-orcid":false,"given":"Max","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna , Wahringer Gurtel 18-20, A-1090 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Madonna","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa , Via Savi 10, 56124 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Delmas","sequence":"additional","affiliation":[{"name":"Cardiology Department, Toulouse University Hospital , 1 Avenue du Pr Jean Poulhes, 31400 Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Schaubroeck","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent University , Corneel Heymanslaan 10, 9000 Ghent ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Morosin","sequence":"additional","affiliation":[{"name":"Heart, Lung and Critical Care Directorates, Royal Brompton Hospital, Royal Brompton & Harefield Hospitals (Part of Guy\u2019s and St Thomas\u2019 NHS Foundation Trust) , Sydney Street, SW3 6NP London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1282-9276","authenticated-orcid":false,"given":"Johann","family":"Wojta","sequence":"additional","affiliation":[{"name":"Core Facilities, Medical University of Vienna , Lazarettgasse 14, 1090 Vienna ,","place":["Austria"]},{"name":"Ludwig Boltzmann Institute for Cardiovascular Research , Wahringer Gurtel 18-20, 1090 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vandenbriele","sequence":"additional","affiliation":[{"name":"Department of Critical Care, Harefield Hospital, Guy's and St Thomas\u2019 NHS Foundation Trust , Hill End Road, Harefield, UB9 6JH Uxbridge ,","place":["UK"]},{"name":"Heart Center Aalst, Azorg Hospital , Moorselbaan 164, 9300 Aalst ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7141-5209","authenticated-orcid":false,"given":"Mathieu","family":"Kerneis","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP) , 47-83 boulevard de l\u2032H\u00f4pital, 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-9617","authenticated-orcid":false,"given":"George","family":"Lazaros","sequence":"additional","affiliation":[{"name":"First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens , 114 Vasilissis Sofias Avenue, 11527 Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Evans","sequence":"additional","affiliation":[{"name":"Biochemical Pharmacology, William Harvey Research Institute, Barts & the London Faculty of Medicine &Dentistry, Queen Mary University of London, Charterhouse Square , EC1M 6BQ London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-3378","authenticated-orcid":false,"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"3rd Medical Department, Wilhelminenhospital , Montleartstra\u00dfe 37, 1160 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-0981","authenticated-orcid":false,"given":"Christian","family":"Hassager","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet , Blegdamsvej 9, 2100 Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Tarkin","sequence":"additional","affiliation":[{"name":"Victor Phillip Dahdaleh Heart and Lung Research Institute , University of Cambridge, Cambridge Biomedical Campus, Papworth Road, CB2 0BB Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-7803","authenticated-orcid":false,"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht University , Universiteitssingel 40, 6229ER Maastricht, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra Maria","family":"Christodorescu","sequence":"additional","affiliation":[{"name":"Department V: Internal Medicine I, Victor Babes University of Medicine and Pharmacy Timisoara , Piata Eftimie Murgu 2, 300041 Timisoara ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4234-6504","authenticated-orcid":false,"given":"Gal","family":"Tsaban","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev , Soroka Campus, Building M7, P.O. Box 653, 8410501 Beer-Sheva ,","place":["Israel"]},{"name":"Department of Cardiology, Soroka University Medical Center , Rager Boulevard 151, 8410101 Beer-Sheva ,","place":["Israel"]},{"name":"Department of Cardiovascular Medicine, Mayo Clinic , 200 First Street SW, MN 55905, Rochester ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-0245","authenticated-orcid":false,"given":"Massimo","family":"Imazio","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiothoracic Department of Medicine, University of Udine , Piazzale Santa Maria della, Misericordia 15, 33100 Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0843-9512","authenticated-orcid":false,"given":"Alessandro","family":"Sionis","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Universitat Aut\u00f2noma de Barcelona , Carrer de Sant Quinti 89, 08041 Barcelona ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) , Instituto de Salud Carlos III, Monforte de Lemos 3-5, 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026102908181348300_zuag086-B1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/14779072.2017.1273771","article-title":"Anti-inflammatory drugs as promising cardiovascular treatments","volume":"15","author":"Huet","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026102908181348300_zuag086-B2","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.2174\/13816128113199990351","article-title":"Emerging anti-inflammatory therapies for atherosclerosis","volume":"19","author":"Roubille","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2026102908181348300_zuag086-B3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41569-019-0239-5","article-title":"Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes","volume":"17","author":"Souilhol","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026102908181348300_zuag086-B4","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1161\/ATVBAHA.114.303424","article-title":"Mechanoresponsive networks controlling vascular inflammation","volume":"34","author":"Bryan","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026102908181348300_zuag086-B5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/mps5010017","article-title":"In vitro methods for measuring the permeability of cell monolayers","volume":"5","author":"Bednarek","year":"2022","journal-title":"Methods Protoc"},{"key":"2026102908181348300_zuag086-B6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/CS20090557","article-title":"Role of nuclear factor kappaB in cardiovascular health and disease","volume":"118","author":"Van der Heiden","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"2026102908181348300_zuag086-B7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-7258(02)00236-X","article-title":"LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis","volume":"95","author":"Chen","year":"2002","journal-title":"Pharmacol Ther"},{"key":"2026102908181348300_zuag086-B8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00592-017-1063-1","article-title":"HLA, infections and inflammation in early stages of atherosclerosis in children with type 1 diabetes","volume":"55","author":"Odermarsky","year":"2018","journal-title":"Acta Diabetol"},{"key":"2026102908181348300_zuag086-B9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3390\/cells9051127","article-title":"Current understanding of an emerging role of HLA-DRB1 gene in rheumatoid arthritis-from research to clinical practice","volume":"9","author":"Wysocki","year":"2020","journal-title":"Cells"},{"key":"2026102908181348300_zuag086-B10","doi-asserted-by":"crossref","first-page":"110715","DOI":"10.1016\/j.isci.2024.110715","article-title":"Genetic association with autoimmune diseases identifies molecular mechanisms of coronary artery disease","volume":"27","author":"Kerns","year":"2024","journal-title":"iScience"},{"key":"2026102908181348300_zuag086-B11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/cvr\/cvx070","article-title":"Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position paper of the European Society of Cardiology working group on cellular biology of the heart","volume":"113","author":"Perrino","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2026102908181348300_zuag086-B12","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/cvr\/cvac114","article-title":"From novel discovery tools and biomarkers to precision medicine-basic cardiovascular science highlights of 2021\/22","volume":"118","author":"Evans","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026102908181348300_zuag086-B13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.94.5.874","article-title":"Elevated levels of interleukin-6 in unstable angina","volume":"94","author":"Biasucci","year":"1996","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/01.CIR.0000049742.68848.99","article-title":"Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes","volume":"107","author":"de Lemos","year":"2003","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B15","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1001\/jama.286.17.2107","article-title":"Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy","volume":"286","author":"Lindmark","year":"2001","journal-title":"JAMA"},{"key":"2026102908181348300_zuag086-B16","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1161\/01.CIR.0000089100.20182.B7","article-title":"Monocyte chemoattractant protein-1 concentration in coronary sinus blood and severity of coronary disease","volume":"108","author":"Serrano-Martinez","year":"2003","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2023.01.013","article-title":"Impact of air pollution on ischemic heart disease: evidence, mechanisms, clinical perspectives","volume":"366","author":"Montone","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026102908181348300_zuag086-B18","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/CIRCRESAHA.116.309279","article-title":"Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation","volume":"119","author":"Pope","year":"2016","journal-title":"Circ Res"},{"key":"2026102908181348300_zuag086-B19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1177\/2047487320904641","article-title":"Association of short-term exposure to air pollution with myocardial infarction with and without obstructive coronary artery disease","volume":"28","author":"Ishii","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026102908181348300_zuag086-B20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jacc.2020.11.033","article-title":"Short-term exposure to ambient air pollution and mortality from myocardial infarction","volume":"77","author":"Liu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026102908181348300_zuag086-B21","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1161\/CIRCULATIONAHA.121.057179","article-title":"Hourly air pollutants and acute coronary syndrome onset in 1.29 million patients","volume":"145","author":"Chen","year":"2022","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B22","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.jacc.2020.09.535","article-title":"Dietary inflammatory potential and risk of cardiovascular disease among men and women in the U.S","volume":"76","author":"Li","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026102908181348300_zuag086-B23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/01.CIR.99.6.779","article-title":"Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study","volume":"99","author":"de Lorgeril","year":"1999","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00125-022-05651-3","article-title":"Sedentary behaviour and physical activity are associated with biomarkers of endothelial dysfunction and low-grade inflammation-relevance for (pre)diabetes: the Maastricht study","volume":"65","author":"Vandercappellen","year":"2022","journal-title":"Diabetologia"},{"key":"2026102908181348300_zuag086-B25","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/eurheartj\/ehz564","article-title":"Mortality reduction with physical activity in patients with and without cardiovascular disease","volume":"40","author":"Jeong","year":"2019","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B26","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jacc.2017.08.017","article-title":"Physical activity and mortality in patients with stable coronary heart disease","volume":"70","author":"Stewart","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026102908181348300_zuag086-B27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/eurjpc\/zwae123","article-title":"Cost-effectiveness of Mediterranean diet and physical activity in secondary cardiovascular disease prevention: results from the UCC-SMART cohort study","volume":"31","author":"Bonekamp","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026102908181348300_zuag086-B28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000898","article-title":"Confluence of depression and acute psychological stress among patients with stable coronary heart disease: effects on myocardial perfusion","volume":"3","author":"Burg","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026102908181348300_zuag086-B29","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1161\/CIR.0000000000000019","article-title":"Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association","volume":"129","author":"Lichtman","year":"2014","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.genhosppsych.2011.02.007","article-title":"Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research","volume":"33","author":"Meijer","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"2026102908181348300_zuag086-B31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(04)17019-0","article-title":"Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Rosengren","year":"2004","journal-title":"Lancet"},{"key":"2026102908181348300_zuag086-B32","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1001\/jama.289.23.3106","article-title":"Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial","volume":"289","author":"Berkman","year":"2003","journal-title":"JAMA"},{"key":"2026102908181348300_zuag086-B33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jama.288.6.701","article-title":"Sertraline treatment of major depression in patients with acute MI or unstable angina","volume":"288","author":"Glassman","year":"2002","journal-title":"JAMA"},{"key":"2026102908181348300_zuag086-B34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","article-title":"Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records","volume":"9","author":"Pearson-Stuttard","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102908181348300_zuag086-B35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1056\/NEJMc1706292","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"377","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B36","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehn387","article-title":"Adipose tissue dysfunction in obesity, diabetes, and vascular diseases","volume":"29","author":"Hajer","year":"2008","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B37","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"key":"2026102908181348300_zuag086-B38","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Writing Group for the CKD Prognosis Consortium","year":"2023","journal-title":"JAMA"},{"key":"2026102908181348300_zuag086-B39","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41581-022-00621-9","article-title":"Targeting innate immunity-driven inflammation in CKD and cardiovascular disease","volume":"18","author":"Speer","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026102908181348300_zuag086-B40","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.jacc.2024.04.030","article-title":"Association of autoimmune diseases with coronary atherosclerosis severity and ischemic events","volume":"83","author":"Mortensen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102908181348300_zuag086-B41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.immunol.021908.132620","article-title":"Immune and inflammatory mechanisms of atherosclerosis (*)","volume":"27","author":"Galkina","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"2026102908181348300_zuag086-B42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41581-023-00797-8","article-title":"Vascular damage in systemic lupus erythematosus","volume":"20","author":"Ambler","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026102908181348300_zuag086-B43","doi-asserted-by":"crossref","first-page":"S364","DOI":"10.1194\/jlr.R800092-JLR200","article-title":"The role of adaptive T cell immunity in atherosclerosis","volume":"50","author":"Mallat","year":"2009","journal-title":"J Lipid Res"},{"key":"2026102908181348300_zuag086-B44","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.mayocp.2019.01.044","article-title":"Systemic lupus erythematosus and increased prevalence of atherosclerotic cardiovascular disease in hospitalized patients","volume":"94","author":"Katz","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2026102908181348300_zuag086-B45","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.15420\/ecr.2020.44","article-title":"Atherosclerotic cardiovascular disease in rheumatoid arthritis: impact of inflammation and antirheumatic treatment","volume":"16","author":"Kerola","year":"2021","journal-title":"Eur Cardiol"},{"key":"2026102908181348300_zuag086-B46","doi-asserted-by":"crossref","first-page":"1044117","DOI":"10.3389\/fcvm.2022.1044117","article-title":"Association between psoriasis and coronary artery calcification: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026102908181348300_zuag086-B47","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/CIRCRESAHA.124.323891","article-title":"Inflammation in HIV and its impact on atherosclerotic cardiovascular disease","volume":"134","author":"Obare","year":"2024","journal-title":"Circ Res"},{"key":"2026102908181348300_zuag086-B48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/ijr.15.33","article-title":"Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions","volume":"10","author":"Hong","year":"2015","journal-title":"Int J Clin Rheumtol"},{"key":"2026102908181348300_zuag086-B49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","article-title":"Inflammation and atherosclerosis: signaling pathways and therapeutic intervention","volume":"7","author":"Kong","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026102908181348300_zuag086-B50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00011-023-01845-6","article-title":"Inflammation in heart failure: pathophysiology and therapeutic strategies","volume":"73","author":"Boulet","year":"2024","journal-title":"Inflamm Res"},{"key":"2026102908181348300_zuag086-B51","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tem.2013.06.004","article-title":"Translation of hemodynamic stress to sterile inflammation in the heart","volume":"24","author":"Nakayama","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"2026102908181348300_zuag086-B52","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC State-of-the-Art Review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026102908181348300_zuag086-B53","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/ijms25021082","article-title":"The role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease","volume":"25","author":"Zhang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026102908181348300_zuag086-B54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/eurheartj\/ehaf658","article-title":"C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the \u2018SMuRF-less but inflamed\u2019","volume":"47","author":"Ridker","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B55","first-page":"466","article-title":"Role of sub-clinical inflammation and defective cholesterol efflux in myocardial infarction patients without standard modifiable risk factors","volume":"14","author":"Roule","year":"2025","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026102908181348300_zuag086-B56","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/eurheartj\/ehad361","article-title":"Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study","volume":"44","author":"Sanchez-Cabo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/ijms27010535","article-title":"Inflammation and resolution in obesity-related cardiovascular disease","volume":"27","author":"Karakasis","year":"2026","journal-title":"Int J Mol Sci"},{"key":"2026102908181348300_zuag086-B58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B59","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B60","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B61","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B62","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B63","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B64","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"2026102908181348300_zuag086-B65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B66","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B67","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B68","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B69","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","article-title":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"41","author":"Bouabdallaoui","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B70","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/eurheartj\/ehaf174","article-title":"Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis","volume":"46","author":"Samuel","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B71","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B72","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/eurjpc\/zwae376","article-title":"Colchicine in patients with stable coronary disease: should we consider basal inflammation - and how?","volume":"32","author":"Roubille","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026102908181348300_zuag086-B73","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B74","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijcard.2021.07.056","article-title":"The association of air pollutants exposure with subclinical inflammation and carotid atherosclerosis","volume":"342","author":"Oikonomou","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026102908181348300_zuag086-B75","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1805971","article-title":"Coronary CT angiography and 5-year risk of myocardial infarction","volume":"379","author":"Investigators","year":"2018","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B76","first-page":"55","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"13","author":"Byrne","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026102908181348300_zuag086-B77","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(18)31114-0","article-title":"Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data","volume":"392","author":"Oikonomou","year":"2018","journal-title":"Lancet"},{"key":"2026102908181348300_zuag086-B78","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B79","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.amjcard.2009.12.059","article-title":"Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)","volume":"105","author":"Abbate","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026102908181348300_zuag086-B80","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FJC.0000000000001635","article-title":"Interleukin-1 blockade with RPH-104 (goflikicept) in patients with ST-segment elevation myocardial infarction: secondary End points from an international, double-blind, randomized, placebo-controlled, phase 2a study","volume":"84","author":"Abbate","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026102908181348300_zuag086-B81","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B82","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026102908181348300_zuag086-B83","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1186\/s13063-024-08573-0","article-title":"Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial","volume":"25","author":"Kunkel","year":"2024","journal-title":"Trials"},{"key":"2026102908181348300_zuag086-B84","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"2026102908181348300_zuag086-B85","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026102908181348300_zuag086-B86","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.70790","article-title":"A narrative review of the pharmacological potential of dapansutrile, a selective NLRP3 inflammasome inhibitor","volume":"40","author":"Abdelrahman","year":"2026","journal-title":"J Biochem Mol Toxicol"},{"key":"2026102908181348300_zuag086-B87","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/dom.15586","article-title":"The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: a meta-analysis of randomized controlled trials","volume":"26","author":"Buttice","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026102908181348300_zuag086-B88","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/dom.14903","article-title":"Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: a randomized controlled trial","volume":"25","author":"Mashayekhi","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026102908181348300_zuag086-B89","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102908181348300_zuag086-B90","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jacbts.2025.03.010","article-title":"Impact of in-hospital PCSK9 inhibition on myocardial inflammation after myocardial infarction: a randomized clinical trial","volume":"10","author":"Ziogos","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"2026102908181348300_zuag086-B91","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/cvr\/cvz198","article-title":"High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death","volume":"116","author":"Pellicori","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2026102908181348300_zuag086-B92","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.121.054567","article-title":"International observational analysis of evolution and outcomes of chronic stable angina: the multinational CLARIFY study","volume":"144","author":"Mesnier","year":"2021","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B93","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease","volume":"382","author":"Maron","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B94","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1916370","article-title":"Health-Status outcomes with invasive or conservative care in coronary disease","volume":"382","author":"Spertus","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102908181348300_zuag086-B95","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/17843286.2025.2498901","article-title":"Performing intravascular procedures in highly inflammatory patients: think twice","volume":"80","author":"Meylaers","year":"2025","journal-title":"Acta Clin Belg"},{"key":"2026102908181348300_zuag086-B96","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0735-1097(01)01795-8","article-title":"Physical training modulates proinflammatory cytokines and the soluble Fas\/soluble Fas ligand system in patients with chronic heart failure","volume":"39","author":"Adamopoulos","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026102908181348300_zuag086-B97","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1751-7133.2011.00217.x","article-title":"The effect of physical training on systemic proinflammatory cytokine expression in heart failure patients: a systematic review","volume":"17","author":"Smart","year":"2011","journal-title":"Congest Heart Fail"},{"key":"2026102908181348300_zuag086-B98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10741-018-9677-0","article-title":"Effect of aerobic and resistance training on inflammatory markers in heart failure patients: systematic review and meta-analysis","volume":"23","author":"Pearson","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2026102908181348300_zuag086-B99","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/2047487317690458","article-title":"Inflammatory biomarkers and effect of exercise on functional capacity in patients with heart failure: insights from a randomized clinical trial","volume":"24","author":"Fernandes-Silva","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2026102908181348300_zuag086-B100","doi-asserted-by":"crossref","first-page":"1841851","DOI":"10.1161\/CIRCULATIONAHA.120.053318","article-title":"Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (the IMICA trial): a double-blinded, placebo-controlled, single-center, randomized, clinical trial","volume":"143","author":"Meyer","year":"2021","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B101","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026102908181348300_zuag086-B102","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.121.056177","article-title":"Effect of colchicine on myocardial injury in acute myocardial infarction","volume":"144","author":"Mewton","year":"2021","journal-title":"Circulation"},{"key":"2026102908181348300_zuag086-B103","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamacardio.2024.2298","article-title":"Prehospital pulse-dose glucocorticoid in ST-segment elevation myocardial infarction: the PULSE-MI randomized clinical trial","volume":"9","author":"Madsen","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026102908181348300_zuag086-B104","first-page":"843","article-title":"Efficacy and safety of colchicine and spironolactone after myocardial infarction: the CLEAR-SYNERGY trial in perspective","volume":"13","author":"Tardif","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"}],"container-title":["European Heart Journal: Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/advance-article-pdf\/doi\/10.1093\/ehjacc\/zuag086\/70412798\/zuag086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/10\/788\/70412798\/zuag086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/10\/788\/70412798\/zuag086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:18:29Z","timestamp":1793276309000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/15\/10\/788\/8748470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":104,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,31]]},"published-print":{"date-parts":[[2026,10,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuag086","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,31]]}}}